Advances of stanniocalcin 2 in tumors

doi:10.3760/cma.j.issn.1673-422X.2018.10.008

Abstract

Abstract: Stanniocalcin 2, a secreted glycoprotein hormone, has been found to be highly expressed in a variety of human malignancies. Through several signal transdution pathways, stanniocalcin 2 plays important roles in the regulation of many biological events of tumor such as proliferation, apoptosis, invasion and metastasis, hypoxia tolerating and drug resistance, indicating stanniocalcin 2 may be a pivotal node in the molecular regulation network of tumor. Stanniocalcin 2 is expected to become a novel biomarker and therapeutic target for diagnosis and treatment of tumor if the funtional mechanisms of stanniocalcin 2 could be further elaborated.

Key words: Neosplasms, Cell proliferation, Apoptosis, Neoplasm metastasis, Stanniocalcin 2

Yu Jishang, Wu Fan. Advances of stanniocalcin 2 in tumors[J]. Journal of International Oncology, 2018, 45(10): 615-618.

References

［1］ Chu SJ, Zhang J, Zhang R, et al. Evolution and functions of stanniocalcins in cancer［J］. Int J Immunopathol Pharmacol, 2015, 28(1): 14-20. DOI: 10.1177/0394632015572745. ［2］ Na SS, Aldonza MB, Sung HJ, et al. Stanniocalcin2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression［J］. Biochim Biophys Acta, 2015, 1854(6): 668676. DOI: 10.1016/j.bbapap.2014.11.002. ［3］ Zhang ZH, Wu YG, Qin CK, et al. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma［J］. Oncol Lett, 2014, 8(5): 2160-2164. DOI: 10.3892/ol.2014.2520. ［4］ Chen B, Zeng X, He Y, et al. STC2 promotes the epithelialmesenchymal transition of colorectal cancer cells through AKTERK signaling pathways［J］. Oncotarget, 2016, 7(44): 71400-71416. DOI: 10.18632/oncotarget.12147. ［5］ Wu J, Lai M, Shao C, et al. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of highgrade serous ovarian cancer［J］. Oncol Rep, 2015, 34(3): 1494-1502. DOI: 10.3892/or.2015.4120. ［6］ Semaan A, Goltz D, Branchi V, et al. Clinicopathological significance of stanniocalcin2 expression in adenocarcinomas of biliary tract［J］. Int J Clin Exp Pathol , 2016, 9(8): 8351-8358. ［7］ Shen XJ, Gu K, Shi JP, et al. Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma［J］. Int J Clin Exp Pathol, 2014, 7(12): 8770-8776. ［8］ Hashemzadeh S, Arabzadeh AA, Estiar MA, et al. Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer［J］. Med Oncol, 2014, 31(10): 237. DOI: 10.1007/s12032-014-0237-8. ［9］ Wang Y, Gao Y, Cheng H, et al. Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer［J］. Biochem Biophys Res Commun, 2015, 466(3): 362-368. DOI: 10.1016/j.bbrc.2015.09.029. ［10］ Yang S, Ji Q, Chang B, et al. STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling［J］. Oncotarget, 2017, 8(4): 5976-5991. DOI: 10.18632/oncotarget.13355. ［11］ Wu F, Li TY, Su SC, et al. STC2 as a novel mediator for Mus81dependent proliferation and survival in hepatocellular carcinoma［J］. Cancer Lett, 2017, 388: 177-186. DOI: 10.1016/j.canlet.2016.11.039. ［12］马翔, 陈双倩, 王国洲, 等. 斯钙素2蛋白在结直肠癌中表达及其临床意义［J］. 中华实验外科杂志, 2015, 32(7): 1701-1703. DOI: 10.3760/cma.j.issn.1001-9030.2015.07.072. ［13］ Singh M, Yelle N, Venugopal C, et al. EMT: mechanisms and therapeutic implications［J］. Pharmacol Ther, 2018, 182: 80-94. DOI: 10.1016/j.pharmthera.2017.08.009. ［14］ Hou J, Wang Z, Xu H, et al. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin1mediated signaling［J］. PLoS One, 2015, 10(4): e0122179. DOI: 10.1371/journal.pone.0122179. ［15］ Vaupel P, Mayer A. Tumor hypoxia: causative mechanisms, microregional heterogeneities, and the role of tissuebased hypoxia markers［J］. Adv Exp Med Biol, 2016, 923: 77-86. DOI: 10.1007/978-3-319-38810-6_11. ［16］ Law AY, Wong CK. Stanniocalcin2 is a HIF1 target gene that promotes cell proliferation in hypoxia［J］. Exp Cell Res, 2010, 316(3): 466-476. DOI: 10.1016/j.yexcr.2009.09.018. ［17］ Law AY, Wong CK. Stanniocalcin2 promotes epithelialmesenchymal transition and invasiveness in hypoxic human ovarian cancer cells［J］. Exp Cell Res, 2010, 316(20): 3425-3434. DOI: 10.1016/j.yexcr.2010.06.026. ［18］ Miyazaki S, Kikuchi H, Iino I, et al. AntiVEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts［J］. Int J Cancer, 2014, 135(2): 295307. DOI: 10.1002/ijc.28686. ［19］ Yuan Q, Zhan L, Zhang LL, et al. Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating Pglycoprotein［J］. Can J Physiol Pharmacol, 2016, 94(9): 929935. DOI: 10.1139/cjpp20150530. ［20］ Cheng H, Wu Z, Wu C, et al. Overcoming STC2 mediated drug resistance through drug and gene codelivery by PHBPDMAEMA cationic polyester in liver cancer cells［J］. Mater Sci Eng C Mater Biol Appl, 2018, 83: 210-217. DOI: 10.1016/j.msec.2017.08.075. ［21］ Law AY, Wong CK. Stanniocalcin1 and 2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways［J］. Mol Cell Endocrinol, 2013, 374(1-2): 7381. DOI: 10.1016/j.mce.2013.04.024. ［22］ Kim PH, Na SS, Lee B, et al. Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress［J］. BMB Rep, 2015, 48(12): 702-707. ［23］ Feng L, Ma J, Ji H, et al. MiR184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin2［J］. Pathol Oncol Res, 2018, 24(4): 853-860. DOI: 10.1007/s12253-017-0298-z. ［24］张存良, 关中, 彭解人. 斯钙素2在喉鳞状细胞癌中的表达及预后的相关性研究［J］. 临床耳鼻咽喉头颈外科杂志, 2015, 29(2): 102-107. DOI: 10.1320/j.issn.1001-1781.2015.02.002. ［25］ Lin S, Guo Q, Wen J, et al. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas［J］. J Exp Clin Cancer Res, 2014, 33(1): 26. DOI: 10.1186/1756-9966-33-26. ［26］ Fang Z, Tian Z, Luo K, et al. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients［J］. Chin J Cancer Res, 2014, 26(5): 602-610. DOI: 10.3978/j.issn.10009604.2014.10.08.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[3]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong. Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway [J]. Journal of International Oncology, 2024, 51(1): 21-28.
[6]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong. Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells [J]. Journal of International Oncology, 2023, 50(9): 513-519.
[7]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[8]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[9]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu. Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells [J]. Journal of International Oncology, 2023, 50(7): 413-418.
[10]	Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping. Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells [J]. Journal of International Oncology, 2023, 50(5): 257-262.
[11]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[12]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[13]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[14]	Zhu Yi, Chen Jian. Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects [J]. Journal of International Oncology, 2023, 50(12): 729-733.
[15]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.